News

Public · Published

AdaptHealth Corp. Stock 12‑Month Price Target Raised to $8.86, Implies 41% Upside

Analysts' average 12-month price target for AdaptHealth Corp. rose from $8.71 to $8.86, according to estimates from seven analysts. The new target implies about 41% potential upside from the Nov. 3 closing price; forecasts range from $8 to $10 per share, and all seven analysts rate the stock Buy.

Published:

Updated:

What happened

Analysts’ average 12-month price target for AdaptHealth Corp. rose from $8.71 to $8.86, according to estimates from seven analysts. The new target implies about 41% potential upside from the Nov. 3 closing price; forecasts range from $8 to $10 per share, and all seven analysts rate the stock Buy.

Confirmed

Global impact / market context

A higher analyst target can influence investor expectations and buying or selling decisions, potentially affecting AdaptHealth’s share price. The target is a forecast, not a promised return, and the seven Buy ratings reflect analyst views rather than evidence that the company’s sales, costs, or cash available have changed.

Analyst inference

The reported outlook is based on seven analysts, with forecasts spanning $8 to $10, so the average target masks differing views. Its implied upside depends on the Nov. 3 closing price; the supplied article gives no company operating results or explanation for the target increase.

Analyst inference

What to watch

  1. Check whether future analyst targets and ratings change, and whether analysts explain those revisions with new information about AdaptHealth’s business or financial performance. Analyst inference
  2. Compare later company disclosures on revenue, costs, and cash available with the assumptions behind analyst forecasts; the article provides no operating details supporting the higher target. Analyst inference
  3. The stated 41% potential upside is measured against the Nov. 3 closing price, so a different share price would change the implied percentage even if the target stayed at $8.86. Confirmed

Evidence

  • Original source link unavailable